Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
Throughout the last three months, 11 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 7 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 2 | 5 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.82, a high estimate of $97.00, and a low estimate of $60.00. This current average has increased by 13.27% from the previous average price target of $61.64.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Crinetics Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | $60.00 |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | $80.00 |
| Leland Gershell | Oppenheimer | Raises | Outperform | $74.00 | $55.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | $60.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | $60.00 |
| Brian Skorney | Baird | Raises | Outperform | $62.00 | $52.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $70.00 | $50.00 |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $65.00 | $65.00 |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | $80.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | $60.00 |
| Yasmeen Rahimi | Piper Sandler | Raises | Overweight | $97.00 | $56.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crinetics Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Crinetics Pharmaceuticals compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Crinetics Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Crinetics Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Crinetics Pharmaceuticals analyst ratings.
Unveiling the Story Behind Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Financial Insights: Crinetics Pharmaceuticals
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, Crinetics Pharmaceuticals faced challenges, resulting in a decline of approximately -76.11% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Crinetics Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -10457.81%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -9.47%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Crinetics Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.3%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Crinetics Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.